KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Income from Continuing Operations (2023 - 2025)

Biocryst Pharmaceuticals' Income from Continuing Operations history spans 9 years, with the latest figure at 245845000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 1017.5% year-over-year to 245845000.0; the TTM value through Dec 2025 reached 263861000.0, up 396.87%, while the annual FY2025 figure was 263861000.0, 396.87% up from the prior year.
  • Income from Continuing Operations reached 245845000.0 in Q4 2025 per BCRX's latest filing, up from 12899000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 245845000.0 in Q4 2025 to a low of 170426000.0 in Q4 2023.
  • Average Income from Continuing Operations over 3 years is 506000.0, with a median of 12674000.0 recorded in 2024.
  • Peak YoY movement for Income from Continuing Operations: skyrocketed 84.28% in 2024, then soared 1017.5% in 2025.
  • A 3-year view of Income from Continuing Operations shows it stood at 170426000.0 in 2023, then surged by 84.28% to 26795000.0 in 2024, then skyrocketed by 1017.5% to 245845000.0 in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Income from Continuing Operations are 245845000.0 (Q4 2025), 12899000.0 (Q3 2025), and 5085000.0 (Q2 2025).